Teva Pharmaceutical Industries News

The Federal Trade Commission requested additional information from Teva Pharmaceutical Industries Ltd.

Sep 2, 2008 - IVAX Diagnostics, Inc. announced that today a group controlled by two experienced and well-known international medical diagnostics and pharmaceutical industry entrepreneurs, Paul Kennedy and ...

Ivax Diagnostics announced Tuesday that a group, controlled by entrepreneurs Paul Kennedy and Patrice Debregeas, purchased all of the nearly 72 percent of the outstanding shares of Ivax Diagnostics from Teva ...

Drug developer Teva Pharmaceutical Industries Inc. spent $490,000 in the second quarter to lobby on various generic drug and federal reimbursement issues, according to a recent disclosure form.

Teva Pharmaceutical Industries Ltd. said Tuesday its Azilect pill is the first to slow the progression of Parkinson's disease in new findings that may increase sales of the medicine to more than $1 billion.

The sales were part of Schering's commitment to the EU to sell some of the products it received in its acquisition of the Organon BioSciences unit of Akzo Nobel in order to eliminate antitrust issues.

By Bill Berkrot

NEW YORK (Reuters) - Teva Pharmaceutical Industries Ltd sued Swiss drugmaker Novartis AG and Momenta Pharmaceuticals Inc on Thursday, accusing them of infringing patents on its multiple sclerosis drug Copaxone.

Israel-based Teva had said in July it intended to sue after the Sandoz unit of Novartis applied to U.S. regulators to sell a generic version of the medicine.

The lawsuit, filed in U.S. District Court in Manhattan, claims that any generic version of Copaxone infringes patents that Teva contends are valid and enforceable.

It's not good enough to just see top-line results ; sometimes the nitty gritty details -- only seen once the full results are presented at a conference -- are more important.

Teva Pharmaceutical Industries Ltd. said Tuesday its drug Azilect slowed the progression of Parkinson's disease and reached all its goals in a late stage clinical trial.

Israeli stocks fell on Tuesday, a day after the government passed a rather tenuous 2009 budget proposal and the Bank of Israel lifted interest rates a quarter percentage point to dampen inflation.

Abbott's cuts are particularly interesting because the company doesn't seem to be in trouble, like the other drugmakers mentioned are.

Might be time to buy calls of Teva Pharmaceutical, the world's leading generic-drug maker.

SCI Corporation announced today that it has entered into an exclusive licensing agreement with Teva Pharmaceutical Industries Ltd.

A recent cross-border merger met some thorny IRS requirements including passing the Helen of Troy test to capture tax-free status as a reorganization.

What have been the best stocks to own in this new millennium, by all accounts the most Britney-filled of all the millennia on record so far? And what, if anything, can we learn by simply running a couple of ...

LONDON : European stocks rose Friday, led by consumer-goods companies, as falling commodity prices eased concern that inflation would force central banks to lift interest rates.

Well, the market was in the dumps yesterday and is even worse today. So this may be a good time to check on my list of stocks for those looking for equities that are stable enough to ride out this bearish ...

Shares of Par Pharmaceutical plunged today after the generic drug developer reported a second-quarter loss and slashed its outlook because of tougher competition and pricing pressure.

There are some 24 million Americans afflicted with diabetes, according to the American Diabetes Association, and it's estimated an additional 1 million cases are reported each year at a cost to public health of ...

Gary Gordon, author of the ETF Expert blog, highlights an eclectic mix of exchange-traded funds that have posted gains so far this year despite the down market: 1. iShares Biotechnology Fund .